undamentalytics Newsletter
Sign in

Phathom Pharmaceuticals, Inc. revenue

Phathom Pharmaceuticals, Inc.'s revenue was $175m in fiscal 2025, up 216.9% on the year before. Over the last twelve months it was $275m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue0155175275
Growth on the year before——+>999%+216.9%—
Gross profit0147153222
Gross margin—75.5%85.6%87.1%80.7%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Phathom Pharmaceuticals, Inc. $275m 86.8% —
Protagonist Therapeutics, Inc $282m 34.8% —
Syndax Pharmaceuticals Inc $290m 159.7% 177.8%
Ligand Pharmaceuticals Inc $254m 1.0% 18.2%
Vir Biotechnology, Inc. $303m 1495.9% -14.8%
Vericel Corp $306m 23.0% 19.8%

Compare with peers

Head to head: PHAT vs PTGXPHAT vs SNDXLGND vs PHAT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Phathom Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Phathom Pharmaceuticals, Inc.